Replay
10 second
10 second
Annotation
00:00 / 00:00
Oral insulin can be a blockbuster opportunity: Kiran Mazumdar-Shaw
Biocon has just brought in Bristol Meyers as a partner for its oral insulin drug. Bristol will fund the clinical trials and, if successful, the rest of the deal will be triggered. Kiran Mazumdar-Shaw, CMD, Biocon, is hopeful of the same and thinks this is a blockbuster opportunity.
